Singapore, Dec 2025 — ChemT Biotechnology, a first mover in AI-designed small-molecule modulators for biologics manufacturing, and CARsgen Therapeutics, a global biopharmaceutical company dedicated to innovative CAR-T therapies, have entered into a strategic partnership focused on accelerating next-generation cell therapy development and exploring potential IND-enabling collaboration opportunities.

This partnership brings together ChemT’s proprietary AI Virtual Cell platform — which creates tunable, pathway-specific small molecules to enhance cell proliferation, persistence, and functional performance — with CARsgen’s deep expertise in CAR-T engineering, translational development, and clinical advancement. Together, the companies aim to enable more robust, efficient, and scalable processes across the cell therapy lifecycle.

For CARsgen, the collaboration provides access to ChemT’s rapidly expanding suite of cell-modulating molecules, including Chemplify™, which has demonstrated the ability to enhance T-cell expansion, reduce exhaustion and senescence, and improve in vitro and in vivo performance. For ChemT, the partnership opens the opportunity to work alongside a global leader in CAR-T therapy development to evaluate how AI-powered Cellular Drug solutions can support future IND strategies and create differentiated next-generation products.

This strategic partnership reflects a shared commitment to advancing scientific innovation and delivering transformative therapies to patients worldwide.